Bacterial infections inflammation
Conditions
Interventions
1) Treatment with the revised reduced doses of ciprofloxacin for adult patients
with impaired renal function receiving study medication at AMC or OLVG location
Oost and recieving standard of care at
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - being treated with ciprofloxacin intravenously (iv) or orally (po) as part of standard care - age >= 18 years - being admitted to general wards of the Amsterdam UMC - location AMC, the OLVG- location Oost or Noordwest Ziekenhuisgroep location Alkmaar - informed consent is obtained
Exclusion criteria
Exclusion criteria: - receiving renal replacement therapy (i.e. haemodialysis, peritoneal dialysis, continuous venovenous hemofiltration or another way of renal replacement therapy), during the first 48 hours of treatment with ciprofloxacin - patients with cystic fibrosis (CF) - informed consent is not obtained
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Drug exposure in the first 24 hours of treatment (AUC0-24) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Drug exposure after 24-48 hours of treatment (AUC24-48) 2) Attainment of relevant PK-PD targets: · AUC / MIC >= 125 · peak concentration (Cmax) / MIC >= 8 3) Adverse effects or toxicity-related problems possibly attributed to treatment with ciprofloxacin | — |
Countries
Netherlands
Outcome results
None listed